GALT mutations cause classic galactosaemia (MIM 230400), the pathological driver of which is partly attributed to the toxicity of accumulating substrate (galactose-1-phosphate, Gal-1-P) from defective GALT enzyme, hence the approach of inhibiting upstream GALK1 to attenuate Gal-1-P levels has been proposed as SRT [69]. Here, GALT is linked to galactosemia.